Trial · NCT07913919
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
NCT07913919, Not applicable, Recruiting, University of Cambridge
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study. Trials, record NCT07913919. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913919
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
- NCT number
- NCT07913919
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 15 participants, estimated
- Lead sponsor
- University of Cambridge
- Conditions
- Systemic Lupus Erythematosus, Atherosclerosis Generalized
- Interventions
- 68-Gallium Dotatate, Anifrolumab
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparison of coronary artery 68Ga-DOTATATE maximum tissue-to-blood ratio (TBRmax) after 16 weeks of anifrolumab compared to baseline | Between baseline and following 16 weeks of anifrolumab therapy | |
| Secondary | Comparison of ascending aortic 68Ga-DOTATATE TBRmax after 16 weeks of anifrolumab compared to baseline | Between baseline and 16 weeks of anifrolumab therapy | |
| Other | Comparison of abdominal aortic and/or renal artery and/or other arterial 68Ga-DOTATATE TBRmax after 16 weeks of anifrolumab compared to baseline | Between baseline and following 16 weeks of anifrolumab therapy | |
| Other | Correlation of arterial 68Ga-DOTATATE TBRmax with clinical disease activity graded by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and/or British Isles Lupus Assessment Group (BILAG) | Between baseline and following 16 weeks of anifrolumab therapy | |
| Other | Correlation of arterial 68Ga-DOTATATE TBRmax with blood markers of systemic inflammation | Between baseline and following 16 weeks of anifrolumab treatment | |
| Other | Comparison of inflammation assessed by 68Ga-DOTATATE PET/MRI (aortic, bone marrow and mediastinal lymph node signals) in patients with coronary artery disease and/or myocardial involvement in SLE versus those without | At baseline - single time point | |
| Other | Comparison of serum lipids at baseline and follow-up | At baseline and following 16 weeks of anifrolumab therapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913919
GET https://conductscience.org/api/trials/v1/NCT07913919/registered